在原发性干燥综合征患者中，利妥昔单抗治疗后血清BAFF水平升高，而APRIL水平未升高：来自一项安慰剂对照临床试验的数据。 - Suppr

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

作者信息

Pollard Rodney P E, Abdulahad Wayel H, Vissink Arjan, Hamza Nishath, Burgerhof Johannes G M, Meijer Jiska M, Visser Annie, Huitema Minke G, Spijkervet Fred K L, Kallenberg Cees G M, Bootsma Hendrika, Kroese Frans G M

出版信息

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31.

DOI:10.1136/annrheumdis-2012-202071

PMID:22851468

Abstract

摘要

相似文献

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31.

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314.

[Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].

Therapie. 2010 Nov-Dec;65(6):581-3. doi: 10.2515/therapie/2010064.

Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.

Arthritis Rheum. 2013 Apr;65(4):1097-106. doi: 10.1002/art.37850.

BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.

Arthritis Rheum. 2007 May;56(5):1464-77. doi: 10.1002/art.22603.

Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance.

Arthritis Res Ther. 2012 Apr 24;14(2):R86. doi: 10.1186/ar3810.

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Arthritis Res Ther. 2006;8(6):R167. doi: 10.1186/ar2076.

Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.

Rheumatology (Oxford). 2014 Jul;53(7):1349-50. doi: 10.1093/rheumatology/ket458. Epub 2014 Jan 20.

Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.

Arthritis Rheumatol. 2015 Jun;67(6):1623-8. doi: 10.1002/art.39088.

Treatment approaches in primary Sjogren syndrome.

JAMA. 2010 Nov 10;304(18):2015-6; author reply 2016. doi: 10.1001/jama.2010.1582.

引用本文的文献

Investigative biological therapies for primary Sjögren's syndrome.

Arch Med Sci. 2020 Jul 15;20(2):506-516. doi: 10.5114/aoms.2020.97288. eCollection 2024.

Features of BAFF and APRIL receptors on circulating B cells in antineutrophil cytoplasmic antibody-associated vasculitis.

Clin Exp Immunol. 2023 Jul 5;213(1):125-137. doi: 10.1093/cei/uxad024.

Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Clin Exp Med. 2023 Sep;23(5):1801-1813. doi: 10.1007/s10238-022-00908-y. Epub 2022 Oct 11.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG Monoclonal Antibody, in Healthy Volunteers.

Kidney Int Rep. 2022 Feb 8;7(5):993-1003. doi: 10.1016/j.ekir.2022.01.1073. eCollection 2022 May.

New developments in Sjogren's syndrome.

Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi53-vi61. doi: 10.1093/rheumatology/keab466.

Rituximab Therapy for Primary Sjögren's Syndrome.

Front Pharmacol. 2021 Sep 2;12:731122. doi: 10.3389/fphar.2021.731122. eCollection 2021.

Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.

Kidney360. 2020 May;1(5):389-398. doi: 10.34067/kid.0001082019. Epub 2020 May 28.

Current and future therapies for primary Sjögren syndrome.

Nat Rev Rheumatol. 2021 Aug;17(8):475-486. doi: 10.1038/s41584-021-00634-x. Epub 2021 Jun 29.

Sjögren's syndrome: a systemic autoimmune disease.

Clin Exp Med. 2022 Feb;22(1):9-25. doi: 10.1007/s10238-021-00728-6. Epub 2021 Jun 7.

Role of the Innate Immunity Signaling Pathway in the Pathogenesis of Sjögren's Syndrome.

Int J Mol Sci. 2021 Mar 17;22(6):3090. doi: 10.3390/ijms22063090.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

作者信息

出版信息

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31.

DOI:10.1136/annrheumdis-2012-202071

PMID:22851468

Abstract

摘要

相似文献

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31.

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314.

[Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].

Therapie. 2010 Nov-Dec;65(6):581-3. doi: 10.2515/therapie/2010064.

Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.

Arthritis Rheum. 2013 Apr;65(4):1097-106. doi: 10.1002/art.37850.

BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.

Arthritis Rheum. 2007 May;56(5):1464-77. doi: 10.1002/art.22603.

Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance.

Arthritis Res Ther. 2012 Apr 24;14(2):R86. doi: 10.1186/ar3810.

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Arthritis Res Ther. 2006;8(6):R167. doi: 10.1186/ar2076.

Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.

Rheumatology (Oxford). 2014 Jul;53(7):1349-50. doi: 10.1093/rheumatology/ket458. Epub 2014 Jan 20.

Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.

Arthritis Rheumatol. 2015 Jun;67(6):1623-8. doi: 10.1002/art.39088.

Treatment approaches in primary Sjogren syndrome.

JAMA. 2010 Nov 10;304(18):2015-6; author reply 2016. doi: 10.1001/jama.2010.1582.

引用本文的文献

Investigative biological therapies for primary Sjögren's syndrome.

Arch Med Sci. 2020 Jul 15;20(2):506-516. doi: 10.5114/aoms.2020.97288. eCollection 2024.

Features of BAFF and APRIL receptors on circulating B cells in antineutrophil cytoplasmic antibody-associated vasculitis.

Clin Exp Immunol. 2023 Jul 5;213(1):125-137. doi: 10.1093/cei/uxad024.

Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Clin Exp Med. 2023 Sep;23(5):1801-1813. doi: 10.1007/s10238-022-00908-y. Epub 2022 Oct 11.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG Monoclonal Antibody, in Healthy Volunteers.

Kidney Int Rep. 2022 Feb 8;7(5):993-1003. doi: 10.1016/j.ekir.2022.01.1073. eCollection 2022 May.

New developments in Sjogren's syndrome.

Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi53-vi61. doi: 10.1093/rheumatology/keab466.

Rituximab Therapy for Primary Sjögren's Syndrome.

Front Pharmacol. 2021 Sep 2;12:731122. doi: 10.3389/fphar.2021.731122. eCollection 2021.

Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.

Kidney360. 2020 May;1(5):389-398. doi: 10.34067/kid.0001082019. Epub 2020 May 28.

Current and future therapies for primary Sjögren syndrome.

Nat Rev Rheumatol. 2021 Aug;17(8):475-486. doi: 10.1038/s41584-021-00634-x. Epub 2021 Jun 29.

Sjögren's syndrome: a systemic autoimmune disease.

Clin Exp Med. 2022 Feb;22(1):9-25. doi: 10.1007/s10238-021-00728-6. Epub 2021 Jun 7.

Role of the Innate Immunity Signaling Pathway in the Pathogenesis of Sjögren's Syndrome.

Int J Mol Sci. 2021 Mar 17;22(6):3090. doi: 10.3390/ijms22063090.

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

作者信息

出版信息

相似文献

引用本文的文献